Document is current
Any future updates will be listed below
-
Authors
Wang, Vicki
Tseng, Kuan-Yin
Kuo, Tung-Tai
Huang, Eagle Yi-Kung
Lan, Kuo-Lun
Chen, Zi-Rong
Ma, Kuo-Hsing
Greig, Nigel H.
Jung, Jin
Choi, Ho-II
Olson, Lars
Hoffer, Barry J.
Chen, Yuan-Hao http://orcid.org/0000-0002-0570-4328
-
Funding
Funding for this research was provided by:
Tri-Service General Hospital (TSGH-D-112095, TSGH-C01-112024)
Ministry of Science and Technology, Taiwan (MOST 109-2314-B-016 -019 -MY2, MOST 111-2314-B-016-057, NSTC 112-2314-B-016 -068 -MY3)
National Defense Medical Center (MAB_D_112004, MND-MAB-C05-112019)
National Institute on Aging (AG000333)
Technological Innovation R&D Program (S2174574)
Bio and Medical Technology Development Program (NRF-2014M3A9B5073868)
- License Information
-
More Information
Article History
Received: 8 December 2023
Accepted: 22 March 2024
First Online: 17 April 2024
Declarations
:
: All animal protocols were approved by the NDMC Animal Care and Use Committee (IACUC 20-128 and IACUC 22-008) in accordance with NIH guidelines (DHEW publications 85-23) Animals were house in our AAALAC accredited animal facility at NDMC). No human subjects.
: Not applicable (the manuscript does not contain any individual person’s data in any form).
: H-I.C. and J.J. are employees of Peptron Inc. The Intramural Research Program of the National Institute on Aging, N.I.H., and Peptron Inc. have a Cooperative Research and Development Agreement to develop Exenatide as a treatment strategy for neurodegenerative disorders for which NIA and Peptron Inc. hold patent rights via the work of H-I.C. and N.H.G. All other authors report no competing interests.
